A5007294283- HIV/AIDS Research and Interventions
- HIV, Drug Use, Sexual Risk
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- Opioid Use Disorder Treatment
- Sex work and related issues
- Homelessness and Social Issues
- SARS-CoV-2 and COVID-19 Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Hepatitis C virus research
- COVID-19 Clinical Research Studies
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- COVID-19 Impact on Reproduction
- Substance Abuse Treatment and Outcomes
- Mental Health and Patient Involvement
- Primary Care and Health Outcomes
- Vaccine Coverage and Hesitancy
- Pharmacological Effects and Toxicity Studies
- Adolescent Sexual and Reproductive Health
- Global Health Workforce Issues
- Migration, Health and Trauma
- HIV/AIDS oral health manifestations
- Health disparities and outcomes
AIDS Vancouver
2016-2025
St. Paul's Hospital
2014-2025
University of British Columbia
2016-2025
Vancouver Coastal Health
2014-2024
University of Chile
2024
Instituto de Salud Pública de Chile
2024
Provincial Health Services Authority
2023
BC Mental Health & Substance Use Services
2023
Response Biomedical (Canada)
2023
Indivior (United States)
2023
Background There has been renewed call for the global expansion of highly active antiretroviral therapy (HAART) under framework HIV treatment as prevention (TasP). However, population-level sustainability this strategy not characterized. Methods We used longitudinal data from province-wide registries including plasma viral load, CD4 count, drug resistance, HAART use, diagnoses, AIDS incidence, and HIV-related mortality. fitted two Poisson regression models over study period, to relate...
Abstract Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain (RBD), ACE2 displacement and viral neutralization activities one month following first second vaccine doses, again 3 months dose, 100 adult PLWH 152 controls. All were receiving suppressive antiretroviral therapy, median CD4+ T-cell counts of 710 (IQR 525–935) cells/mm , though nadir...
To estimate the incidence of and risk factors for emergent resistance to integrase strand transfer inhibitor (INSTI) nucleoside(-tide) reverse transcriptase inhibitors (NRTI) in HIV-1-infected adults receiving an INSTI two NRTIs.Retrospective cohort study.Persons aged at least 19 years were included if they received their first prescription raltegravir, elvitegravir or dolutegravir British Columbia, Canada 2012-2014 followed 31 December 2015. Emergent was defined as new mutations conferring...
Abstract Background Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19) vaccines remain incompletely characterized in people living with human immunodeficiency virus (HIV) (PLWH), as do initial a third dose. Methods We measured antibodies against the severe acute respiratory syndrome 2 (SARS-CoV-2) spike protein receptor-binding domain, angiotensin-converting enzyme (ACE2) displacement, and viral neutralization wild-type Omicron strains up 6 months after vaccination,...
The Comparative Outcomes and Service Utilization Trends (COAST) study compares health outcomes among People With HIV (PWH) Without (PWoH) in British Columbia (BC), Canada. cohort was recently updated to include persons diagnosed with after March 31, 2013, expanded broaden research applications. COAST includes PWH a 10% random sample of the general population without HIV, all aged ≥19. Our links an registry healthcare practitioner billing, hospital emergency department attendance data,...
Highly active antiretroviral therapy (HAART) represents the single most significant advance in fight against HIV/AIDS. The vast majority of patients treated with HAART will experience long-term remission HIV disease. does not cure course, but it changes disease into a chronic and manageable condition. Use is associated decreased HIV/AIDS-related morbidity, fewer opportunistic infections, reduced mortality. Evidence has also shown that can reduce transmission. This clearly illustrated studies...
The immunogenic nature of coronavirus disease 2019 (COVID-19) mRNA vaccines led to some initial concern that these could stimulate the HIV reservoir. We analyzed changes in plasma loads (pVL) and reservoir size following COVID-19 vaccination 62 people with (PWH) receiving antiretroviral therapy (ART), province-wide trends pVL before after mass campaign.
Objectives: To describe and compare integrase strand transfer inhibitor (INSTI) adverse drug reactions (ADRs) for raltegravir, elvitegravir-cobicistat, dolutegravir. Design: Population-based, retrospective cohort. Methods: Antiretroviral-experienced naive persons at least 19 years old were included if they received their first prescription or dolutegravir in British Columbia, Canada, 2012–2014, followed 2 until 31 December 2016. The primary outcome was an ADR resulting INSTI discontinuation....
Background Late HIV diagnosis is associated with increased AIDS-related morbidity and mortality as well an risk of transmission. In this study, we quantified characterized missed opportunities for earlier in British Columbia (BC), Canada. Design Retrospective cohort. Methods A opportunity was defined a healthcare encounter due to clinical manifestation which may be caused by infection, or frequently present among those but no followed within 30 days. We developed algorithm identify one,...
There is limited research investigating the possible mechanisms of how starting combination antiretroviral therapy (cART) at a higher CD4 cell count decreases mortality. This study investigated association between initiating cART with short-term and long-term achievement viral suppression; emergence any drug resistance an AIDS-defining illness (ADI); treatment adherence; all-cause mortality.This retrospective cohort included 4120 naive patients who initiated 2000 2012. Patients were followed...
Realizing the full individual and population-wide benefits of antiretroviral therapy for human immunodeficiency virus (HIV) infection requires an efficient mechanism HIV-related health service delivery. We developed a system dynamics model continuum HIV care in Vancouver, Canada, which reflects key activities decisions delivery therapy, including testing, linkage to care, long-term retention treatment. To measure influence operational interventions on population outcomes, we incorporated...
HIV-positive people who use illicit drugs (PWUD) experience elevated rates of HIV-associated morbidity and mortality compared with members other key affected populations. Although suboptimal levels access adherence to antiretroviral therapy (ART) are common among PWUD, there is a need for studies investigating the possible biological impacts noninjection drug living HIV in real-world settings.We accessed data from ACCESS study, an ongoing prospective cohort users systematic viral load...
ABSTRACT Background Longer-term humoral responses to two-dose COVID-19 vaccines remain incompletely characterized in people living with HIV (PLWH), as do initial a third dose. Methods We measured antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement and viral neutralization wild-type Omicron strains up six months following vaccination, one month dose, 99 PLWH receiving suppressive antiretroviral therapy, 152 controls. Results Though naturally decline we...
Background: Limited data exist regarding longer term antibody responses following three-dose coronavirus disease 2019 (COVID-19) vaccination, and the impact of a first SARS-CoV-2 infection during this time, in people with HIV (PWH) receiving suppressive antiretroviral therapy (ART). We quantified wild-type-specific, Omicron BA.1-specific BA.5-specific up to 6 months post-third dose 64 PWH 117 controls who remained COVID-19-naive or experienced their time. Design: Longitudinal observational...
Objective: We assessed sex differences in hospitalization rates among people with HIV (PWH) and without (PWoH) British Columbia (BC). Methods: PWH a 10% random sample of PWoH BC aged ≥19 were followed from 04/01/2002 to 03/31/2020, using linked administrative Comparative Outcomes Service Utilization Trends (COAST) study data. Hospitalizations categorized by discharge diagnosis, broad International Classification Diseases-classes. Using Poisson regression, we modelled the association between...
SummaryBackgroundLife expectancy of people with HIV has increased considerably. We used data from the Comparative Outcomes And Service Utilization Trends (COAST) study to examine sex differences in life and mortality between 1996 2020 among British Columbia (BC), Canada.MethodsCOAST, a population-based cohort study, includes clinical administrative health on virtually all BC. calculated for at ages 20, 40, 55 years stratified by calendar period. Cox regression model associations all-cause...
We conducted a strengths-based, qualitative study to elucidate the approaches and strategies utilized by healthcare providers (HCPs) support HIV treatment engagement in British Columbia (BC), Canada. Healthcare (e.g., nurses, peer navigators, pharmacists) across province of BC were recruited through regional programs word mouth purposive sampling strategies. An academic community researcher co-conducted semi-structured phone interviews with HCPs providing HIV-specific healthcare. Emergent...
Abstract Introduction Antiretroviral therapy ( ART ) scale‐up is central to the global strategy control HIV / AIDS pandemic. To accelerate efforts towards ending epidemic, Joint United Nations Programme on released 90‐90‐90 and 95‐95‐95 targets, which have recently been approved by UN ). This study characterizes province of British Columbia BC )'s progress achieving predicts a trajectory up 2030 according each individual steps (i.e. %Diagnosed, %On %Virologically Suppressed), identifies...